https://canadianallergyandimmunologytoday.com/ Catalytic Health en-US Canadian Allergy & Immunology Today 2563-7711 https://canadianallergyandimmunologytoday.com/article/view/4-s01-ohayon <p class="p1"><span class="s1">T</span>he treatment of hereditary angioedema (HAE) has progressed significantly over the last decade. HAE is an autosomal dominant condition that is bradykinin mediated and affects approximately 1 in 50,000 people.<span class="s2">&nbsp;</span>This condition continues to challenge allergists/immunologists (A/I) in promptly managing the disease to reduce attacks of potentially life-threatening angioedema, while improving quality of life in a population in which disease activity tends to increase with age.<span class="s2">&nbsp;</span>Notably, delays in diagnosis may reach up to 8 years from initial presentation.<span class="s2">&nbsp;</span>The impact of HAE extends beyond the patient, and can affect their caregivers, owing to the fear of acute attacks, which can lead to absenteeism both at school and in the workplace and ultimately negatively impact quality of life and career productivity.</p> Jason Ohayon Copyright (c) 2023 Canadian Allergy & Immunology Today 2024-01-23 2024-01-23 2–8 2–8 10.58931/cait.2024.4s0161